Spero Therapeutics (FRA:2HA) Beginning Cash Position : €48.92 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Spero Therapeutics Beginning Cash Position?

Spero Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2025 was €48.92 Mil.

Spero Therapeutics's quarterly Beginning Cash Position increased from Sep. 2024 (€57.24 Mil) to Dec. 2024 (€72.86 Mil) but then declined from Dec. 2024 (€72.86 Mil) to Mar. 2025 (€48.92 Mil).

Spero Therapeutics's annual Beginning Cash Position declined from Dec. 2022 (€106.28 Mil) to Dec. 2023 (€100.05 Mil) and declined from Dec. 2023 (€100.05 Mil) to Dec. 2024 (€72.90 Mil).

Spero Therapeutics Beginning Cash Position Historical Data

The historical data trend for Spero Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spero Therapeutics Beginning Cash Position Chart

Spero Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Beginning Cash Position

Get a 7-Day Free Trial

24.44

75.41

106.28

100.05

72.90

Spero Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Beginning Cash Position	Get a 7-Day Free Trial															70.23	76.43	57.24	72.86	48.92

Spero Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Spero Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Spero Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Spero Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (FRA:2HA) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

SPRO:USA

Address

675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139

Website

https://www.sperotherapeutics.com

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Spero Therapeutics Headlines

No Headlines